Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Accuses CVS of Defrauding Medicare over Prescriptions

Jonathan Stempel  |  December 18, 2019

NEW YORK, Dec 17 (Reuters)—CVS Health Corp. and its Omnicare unit were sued on Tuesday by the U.S. government, which accused them of fraudulently billing Medicare and Medicaid for hundreds of thousands of drugs without valid prescriptions.

The U.S. Department of Justice joined two whistleblower lawsuits accusing Omnicare of failing to obtain new prescriptions from doctors after old ones expired or ran out of refills.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Instead, the government said Omnicare simply assigned new numbers to old prescriptions, enabling it to dispense drugs for months or years after the prescriptions expired, and submitted false claims to the government healthcare programs for payment on what it called “rollover” prescriptions.

The alleged wrongdoing occurred from 2010 to 2018, according to a complaint filed in Manhattan federal court.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

CVS did not immediately respond to requests for comment.

Reporting by Jonathan Stempel in New York Editing by Chizu Nomiyama and Bill Berkrot

Share: 

Filed under:Legal UpdatesProfessional Topics Tagged with:CVS Health CorpDrugslawsuitLegalMedicaidMedicareOmnicare

Related Articles

    CVS Health to Acquire Aetna for $69 billion

    December 4, 2017

    (Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…

    CVS to Pay $5 Million to Resolve U.S. Drug Probe

    July 12, 2017

    (Reuters)—CVS Health Corp. has paid $5 million to resolve allegations that pharmacies it operates in California failed to keep and maintain accurate records of prescription drugs, the U.S. Justice Department said on Tuesday. The deal follows an investigation that began in 2012 after the U.S. Drug Enforcement Administration noticed an increased number of thefts and unexplained…

    Practice Page: Is In-house or Outsourced Medical Billing Right for Your Physician Practice?

    February 1, 2014

    What to consider when deciding whether to delegate claims billing in-house or to contract with an outside company

    CVS, Aetna Win U.S. Approval for $69 Billion Merger

    October 10, 2018

    WASHINGTON (Reuters)—Pharmacy chain CVS Health Corp won U.S. antitrust approval for its $69 billion acquisition of health insurer Aetna Inc, the Justice Department said on Wednesday, paving the way for a combination the companies say can help cut soaring U.S. healthcare costs. It is the second large recent healthcare deal to win a thumbs up…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences